Aim: Our aim in this study is to investigate the survival-effective prognostic factors of rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Material and Method: A total of 84 patients, including 54 patients with rectal cancer who received neoadjuvant CRT and 30 patients who did not receive it, were included in the study at the Gastroenterology Surgery Clinic of Health Sciences University Koşuyolu Yüksek Ihtisas Training and Research Hospital between January 2019 and October 2019. The data of the patients were retrospectively taken from the hospital automation system and used.
Results: 84 patients were included in our study. Of these patients, 40 were male(47%) and 44 were female(53%). The patients were followed for an average of 44 months. Neoadjuvant chemoradiotherapy treatment was applied to 64.3% of the 84 patients who underwent surgery for rectal cancer. According to Kaplein Meier long rank test analysis, no statistical difference was found in the survival Deciency between the two groups (p=0.115). The average life expectancy of patients receiving neoadjuvant chemoradiotherapy was 66.7±4.8 months, while in patients not receiving neoadjuvant therapy, it was found to be 76.6±4.4 months.
Conclusion: The incidence of rectal cancer is still high today. Neoadjuvant CRT at the local advanced stage is a standard treatment approach. In our study, the most important prognostic factor effective survival after neoadjuvant CRT was found to be the presence of lymph node metastasis after surgery.
Primary Language | English |
---|---|
Subjects | Clinical Sciences (Other) |
Journal Section | Original Articles |
Authors | |
Publication Date | June 14, 2024 |
Submission Date | April 17, 2024 |
Acceptance Date | May 6, 2024 |
Published in Issue | Year 2024 Volume: 1 Issue: 2 |